NCT02853565 - A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions

Glioblastoma Multiforme

Interventions

DRUG

CAN008

The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)

Trial Locations (2)

Chang Gung Memorial Hospital, Linkou, Taipei

National Taiwan University Hospital, Taipei